Premium
Brief report: Lactobacillus bulgaricus GLB 44 (Proviotic ™ ) plus esomeprazole for Helicobacter pylori eradication: A pilot study
Author(s) -
Opekun Antone R.,
Gonzales Savannah A.,
AlSaadi Mahmoud A.,
Graham David Y.
Publication year - 2018
Publication title -
helicobacter
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.206
H-Index - 79
eISSN - 1523-5378
pISSN - 1083-4389
DOI - 10.1111/hel.12476
Subject(s) - esomeprazole , helicobacter pylori , urea breath test , lactobacillus , medicine , breath test , gastroenterology , proton pump inhibitor , microbiology and biotechnology , helicobacter pylori infection , biology , food science , fermentation
Abstract Background Recent studies of Lactobacillus delbrueckii subsp. bulgaricus GLB 44 plus a proton‐pump inhibitor ( PPI ) reported cures of more than 90% of patients with active Helicobacter pylori infections. Aim To confirm the high H. pylori cure rates reported previously. Method A pilot study was done in healthy H. pylori ‐infected volunteers using 3‐gram sachet (3 billion cells) of L. delbrueckii GLB 44 plus 22.3 mg of esomeprazole b.i.d., for 14 days. The result was determined by urea breath testing 4 weeks after therapy. Stopping rules required for ending enrollment if less than 3 of the first 10 subjects were cured. Results Nine subjects were entered and because all failed to achieve negative urea breath test, the stopping rule required the study to end. Conclusion We were unable to confirm reports of achieving a high H. pylori cure rate with L. delbrueckii GLB 44 plus a PPI .